Revisiting Interleukin-12 as a Cancer Immunotherapy Agent
Pedro Berraondo, Iñaki Etxeberria, Mariano Ponz-Sarvise, Ignacio Melero
IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNγ. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer.